EU committee recommends PiaSky approval for teens, adults with PNH
A European Medicines Agency (EMA) committee has recommended the approval of Roche’s PiaSky (crovalimab) to treat people with paroxysmal nocturnal hemoglobinuria (PNH), ages 12 and older, who weigh at least 40 kilograms (88 pounds) — including patients both new to, or previously treated with, C5 inhibitors. The news…